Adverum Biotechnologies (ADVM) PT Lowered to $5 at RBC Capital, Reflecting Increased OpEx
Tweet Send to a Friend
RBC Capital analyst Lisa Walter lowered the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $5.00 (from $10.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
